Senior role supports ambitious commercialisation strategy

Following its $10 million Series A financing  in July 2023, Camena Bioscience has appointed Dr Nicola Thompson as Chair of its Board of Directors as part of plans for commercial expansion of its DNA synthesis platform, gSynth™. Click to read more...

Related Keywords

Steve Harvey ,Camena Bioscience ,Nicola Thompson ,University College London ,Amphista Therapeutics ,Nanna Therapeutics ,Cell Biology ,University College ,With Pharma ,Synthesis ,Wamena ,Hair ,Board ,Ioscience ,Nicola ,Herapeutics ,Technology ,Series ,Thompson ,